ECCN European Conference on Clinical Neuroimaging - Brussels Belgium 2018

Save the date : Brussels, Belgium March, 26-27, 2018


Monday, March, 26

8.30-9.20 a.m.     Registration

9.20-9.30 a.m.     Welcome  

9.30-11.00 a.m.   Lectures: Session 1 Functional connectivity using fMRI, PET and MEG for neurodegenerative diseases
Chair: X. de Tiège

9.30-10.00 a.m.   L1        Functional brain connectivity: theory and investigation using fMRI.
                                          D. Mantini (Leuven, Belgium)
10.00-10.30 a.m. L2        Electrophysiological bases of functional brain connectivity. 
                                          M. Brookes (Nottingham, UK)
10.30-11.00 a.m. L3        Functional brain connectivity alterations along the Spectrum of Alzheimer’s Disease.
                                          W. de Haan (Amsterdam, The Netherlands)
11.00-11.30 a.m. Coffee Break and poster session

11.30-12.10 p.m. Oral communications (Session 1) Chair: X. de Tiège, S. Goldman
11.30-11.40 a.m.   OC1   Brain metabolic connectivity and resting-state networks in  sub-variants of the behavioural fronto-temporal dementia. G. Carli (Italy)
11.40-11.50 a.m.   OC2   Functional connectivity changes in resting state MRI after donepezil    treatment in healthy participants.
P. Péran (France)
11.50-12.00 a.m.   OC3   Multi-network signature reflects clinical heterogeneity in Lewy body dementia. A. Sala (Italy)
12.00-12.10 p.m.   OC4   18F-FDG PET changes of cortical glucose metabolism in typical Versus atypical sporadic forms of early-onset Alzheimer’s Disease. M. Vanhoutte (France)

12:10-13.00pm    Special Lecture (sponsored by GE)
A systematic review and aggregated analysis on the impact of amyloid PET brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s Disease.
E. Fantoni (Amersham, UK)

13.00-2.00 p.m.   Lunch Break and poster session
2.00-3.30 p.m.     Lectures: Session 2 Tau and amyloid PET imaging: when & why? Chair: V. Garibotto

2.00-2.30 p.m.   L4           The roadmap for the use of imaging biomarkers in Alzheimer’s Disease.  
                                            M. Boccardi (Geneva, Switzerland)                                  
2.30-3.00 p.m.   L5           Building evidence for the clinical usefulness of amyloid PET: multicenter          
                                             trials. V. Garibotto (Geneva, Switzerland)
3.00-3.30 p.m.  L6          The use of PET imaging in Alzheimer’s Disease for the clinician.
                                         S. Engelborghs (Antwerp, Belgium)
3.30-4.00 p.m.     Coffee Break and poster session

4.00-5.30 p.m.     Lectures: Session 3 Methodology Chair: A. Lammerstma

4.00-4.30 p.m.  L7      Quantification and clinical PET: friends or foes?
                                       A. Lammertsma (Amsterdam, The Netherlands)
4.30-5:00 p.m. L8       FDG-single-subject Optimized SPM procedure in clinical setting.
                                      D. Perani (Milano, Italy)
5-00-5.30 p.m. L9    PVE correction for amyloid imaging. M. Grothe (Rostock, Germany)

5.30-6.30 p.m.     Oral communications (Session 2)
Chair: M. Boccardi, S. Engelborghs

5.30-5.40 p.m.     OC5     Regional Amyloid Deposition predict Progression from Preclinical to Prodromal Stages of Alzheimer’s Disease. G. Bischof (Germany)
5.40-5.50 p.m.     OC6     Tau accumulation observed using repeated PET measures is associated with cognitive decline in normal elderly. B. Hanseeuw (USA)
5.50-6.00 p.m.     OC7     Brain reserve affects relation between tau pathology and neurodegeneration in Alzheimer’s disease. M. Hönig (Germany)
6.00-6.10 p.m.     OC8     Tau accumulation in clinically normal older adults partially explains the association between hippocampal hyperactivity and ApoE4 status.
                               W. Huijbers (Netherlands)
6.10-6.20 p.m.     OC9     Relationship between csf biomarkers and cerebral metabolism in early onset Alzheimer’s Disease. A. Jaillard (France)
6.20-6.30 p.m.     OC10 Automated volumetric hippocampal measurements in relation to neuropsychological findings in Alzheimer’s Disease – REMEMBER study. E. Niemantsverdriet (Belgium)

Tuesday, March 27, 2018 

8.00-8.40 a.m.     Registration

8.40-9.30 a.m.   Lectures: Session 4 Parkinson Disease and other movement disorders Chair: A. Varrone
8.40-9.10 a.m.   L10         Multimodal Neuroimaging in Atypical Parkinsonism.
                                           T. van Eimeren (Cologne, Germany)
9.10-9.40 a.m.   L11         Development of F18-FE-PE2I : a DAT imaging tool for research and clinical             
                                            applications. A. Varrone (Stockholm, Sweden)
9:40-10.20 a.m. Oral communications (Session 3) Chair: T. van Eimeren, E. Salmon

9.40-9.50 a.m.     OC11     Longitudinal changes of R2 star and diffusion parameters in substantia nigra of Parkinson's disease patients. G. Arribarat (France)
9.50-10.00 a.m.   OC12     Increased age-associated striatal uptake of tau-binding PET tracer [18F]-AV-1451 in Huntington’s disease. K.  Giehl (Germany)
10.00-10.10 a.m. OC13     Dopamine turnover in the ventral striatum is modulated by symptom severity in Parkinson’s patients with impulse control disorders. J. Hammes (Germany)
10.10-10.20 a.m. OC14     Texture and shape analysis of striatum and thalamus in 18F-FDG PET in Parkinson’s Disease, parkinsonian variant of Multiple System Atrophy and Progressive Supranuclear Palsy. F. Hives (France)
10.20-10.30 a.m. OC15     Impact of florbetaben amyloid PET on diagnosis and management of patients with complex clinical profiles: does a relationship with pre-PET diagnostic confidence exist?  A. Perrotin (France)
10.30-11. 00 a.m. Coffee Break and poster session

11.00-12.30 p.m. Lectures: Session 5 Novel brain PET ligands Chair: K. van Laere

11.00- 11:30a.m. L12      Novel/non-TSPO neuroinflammation radioligands.
                                           K. van Laere (Leuven, Belgium)
11.30-12.00 a.m. L13      Synaptic density tracers. E. Salmon (Liège, Belgium)
12.00-12.30 a.m. L14      PET imaging as an enabling technology in CNS drug development: promise and challenges.
​                                         M. Schmidt (Antwerp, Belgium)
12:30-1.30 p.m.   Lunch Break and poster session

1:30-1:50 p.m.     Award Ceremony (Prizes to the best 5 oral presentations)
                             Chair: S. Goldman, F. Semah
1.50-3:10 p.m.     Oral communications (Session 4)
                            Chair: F. Semah, S. Goldman

1.50-2.00 p.m.     OC16        Feasibility of synchronous brain-perfusion-SPECT and EEG measurements in cochlear-implant users to reveal networks of speech understanding during a speech-discrimination task G. Berding (Germany)
2.00-2.10 p.m.     OC17        Evaluation of [18F] FDG-PET biomarker in amyotrophic lateral sclerosis
                            L. Laccarino (Italy)

2.10-2.20 p.m.     OC18        Cross-sectional variations of white and grey matter in older hypertensive patients with subjective memory complaints A. Verger (France)
2.20-2.30 p.m.     OC19        Periventricular microglial activation might drive clinical progression in multiple sclerosis. E. Poirion (France)
2.30-2.40 p.m.     OC20        Comparing predictors of cognitive decline and MCI-to-AD conversion in a 12-month follow-up study.
J. Ottoy (Belgium)
2.40-2.50 p.m.     OC21        TSPO versus P2X7 as target for neuroinflammation – an in vitro and in vivo study.
D. van Weehaeghe (Belgium)
2.50-3.00 p.m.     OC22        Cerebrovascular lesions during normal aging: a neuropathological study with 7.0-tesla magnetic resonance imaging J. De Reuck (Belgium)

3.00-3.10 p.m.     OC23        New prototype of CZT SPECT camera (VERITON®): the revival of SPECT brain nuclear médicine
P. Branger (France)
3:10-3:30 p.m.     Conclusions (S. Goldman, F. Semah)


               Share Share

News | general information | Archives | Press Presse | Newsletters | DOCUMENTS